175 related articles for article (PubMed ID: 25537513)
1. By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.
Petrelli A; Carollo R; Cargnelutti M; Iovino F; Callari M; Cimino D; Todaro M; Mangiapane LR; Giammona A; Cordova A; Montemurro F; Taverna D; Daidone MG; Stassi G; Giordano S
Oncotarget; 2015 Feb; 6(4):2315-30. PubMed ID: 25537513
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
[TBL] [Abstract][Full Text] [Related]
3. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
4. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties.
Hu H; Sun J; Wang C; Bu X; Liu X; Mao Y; Wang H
Biochem Biophys Res Commun; 2017 Apr; 485(3):643-650. PubMed ID: 28216163
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
6. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.
Francescangeli F; Patrizii M; Signore M; Federici G; Di Franco S; Pagliuca A; Baiocchi M; Biffoni M; Ricci Vitiani L; Todaro M; De Maria R; Zeuner A
Stem Cells; 2012 Sep; 30(9):1819-30. PubMed ID: 22753241
[TBL] [Abstract][Full Text] [Related]
7. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
10. PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.
Wierer M; Verde G; Pisano P; Molina H; Font-Mateu J; Di Croce L; Beato M
Cell Rep; 2013 Jun; 3(6):2021-32. PubMed ID: 23770244
[TBL] [Abstract][Full Text] [Related]
11. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
Ren YQ; Wang HJ; Zhang YQ; Liu YB
Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353
[TBL] [Abstract][Full Text] [Related]
12. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
13. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
[TBL] [Abstract][Full Text] [Related]
14. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
15. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity.
Kim J; Villadsen R; Sørlie T; Fogh L; Grønlund SZ; Fridriksdottir AJ; Kuhn I; Rank F; Wielenga VT; Solvang H; Edwards PA; Børresen-Dale AL; Rønnov-Jessen L; Bissell MJ; Petersen OW
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6124-9. PubMed ID: 22454501
[TBL] [Abstract][Full Text] [Related]
16. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
17. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.
Ahmad A; Ginnebaugh KR; Yin S; Bollig-Fischer A; Reddy KB; Sarkar FH
BMC Cancer; 2015 Jul; 15():540. PubMed ID: 26206152
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
19. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion.
Iliopoulos D; Hirsch HA; Wang G; Struhl K
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1397-402. PubMed ID: 21220315
[TBL] [Abstract][Full Text] [Related]
20. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
